A Pilot Study Examining the Impact of the Jakl Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Itacitinib (Primary)
- Indications Leiomyosarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Pharmacodynamics
- 01 Oct 2019 Status changed from not yet recruiting to recruiting.
- 09 Sep 2019 Planned initiation date changed from 31 Aug 2019 to 1 Oct 2019.
- 31 Jul 2019 Planned initiation date changed from 31 Jul 2019 to 31 Aug 2019.